ArticleTherapeutic advances in medical oncology2025
Macrocytosis as a risk factor for secondary esophageal cancer in hypopharyngeal cancer patients: a multicenter case-control study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identification of hypopharyngeal cancer (HPC) patients at heightened risk for developing metachronous second primary esophageal cancer (MSPEC) is crucial for the optimization of screening protocols and thus survival improvement. Although mean corpuscular volume (MCV) is recognized as a biomarker for esophageal cancer, its association with MSPEC among HPC patients remains unexplored. Objective: This study aimed to investigate the predictive value of MCV for MSPEC in HPC patients. Design: In this 19-year retrospective, nested case-control study, HPC patients from the Chang Gung Research Database between January 2001, and December 2019, were examined. Methods: A total of 114 HPC patients who developed MSPEC were matched with 1895 non-MSPEC controls in a 1:3 propensity score-matched analysis. Logistic regression models were deployed to assess the odds of MSPEC manifestation in relation to MCV levels. Results: Matching for clinical characteristics and follow-up periods yielded 96 MSPEC patients and 288 matched controls. Elevated MCV levels were associated with an increased risk of MSPEC, indicating a dose-response relationship. Specifically, MCV ranges from 95 to 100 femtoliters (fL) and ⩾100 fL correlated with adjusted odds ratios for MSPEC of 2.37 (95% confidence interval (CI): 1.33-4.24) and 4.84 (95% CI: 2.62-8.95), respectively. Notably, an MCV ⩾100 fL was a more pronounced predictor of MSPEC among younger patients and those with advanced disease stages. Within the initial cohort of 2009 HPC patients, 31 (2.9%) of 1052 patients with MCV <95 fL developed MSPEC, and 46 (11.5%) of 401 patients with MCV ⩾100 fL experienced MSPEC. Conclusion: Macrocytosis at HPC diagnosis is indicative of an escalated MSPEC risk, underscoring the imperative for intensive surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.